MSH radiopeptides for targeting melanoma metastases

Advances in Experimental Medicine and Biology

Volumn 681, Issue , 2010, Pages 133-142

  Eberle, Alex N ^a   Bapst, Jean Philippe ^b   Calame, Martine ^b   Tanner, Heidi ^b   Froidevaux, Sylvie ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID [BETA ALANYLNORLEUCYLASPARTYL DEXTRO PHENYLALANYLLYSINE] ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ACETYL 4 NORLEUCINE 7 DEXTRO PHENYLALANINE ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ALPHA INTERMEDIN IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYLASPARTYL DEXTRO PHENYLALANINE ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYLASPARTYL DEXTRO PHENYLALANINE ALPHA INTERMEDIN GA 67; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYLASPARTYL DEXTRO PHENYLALANINE ALPHA INTERMEDIN GA 68; [AFAMELANOTIDE(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)] ALPHA INTERMEDIN; ACETYL 4 NORLEUCINE 7 DEXTRO PHENYLALANINE ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; GALACTOSYL [NORLEUCYLASPARTYL DEXTRO PHENYLALANINE(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)] ALPHA INTERMEDIN; INTERMEDIN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER DIAGNOSIS; DRUG ACCUMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; GAMMA RADIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR DOWN REGULATION; TARGET CELL; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MELANOCYTE-STIMULATING HORMONES; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS;

ANIMALIA;

EID: 79959549602     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6354-3_11     Document Type: Article

References (50)

1. Vikram B, Coleman CN, Deye JA. Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources. Oncology (Williston Park) 2009; 23:279-83.
2. Vikram B, Coleman CN, Deye JA. Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site. Oncology (Williston Park) 2009; 23:380-5.
3. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302. (Pubitemid 38541581)
4. Eberle AN, Mild G, Froidevaux S. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: Applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct 2004; 24:319-45.
5. Reubi JC. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med 1995; 36:1825-35.
6. Mariani G, Erba PA, Signore A. Receptor-mediated tumor targeting with radiolabeled peptides: There is more to it than somatostatin analogs. J Nucl Med 2006; 47:1904-6.
7. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: State of science. J Nucl Med 2003; 44:1945-61. (Pubitemid 40022141)
8. Reubi JC, Mäcke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46(Suppl 1):67S-75S. (Pubitemid 47619021)
9. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002; 66:161-83. (Pubitemid 35285217)
10. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004; 80(Suppl 1):51-6.
11. Eberle AN. The melanotropins: Chemistry, physiology and mechanisms of action. Basel: Karger; 1988.
12. Eberle AN, Froidevaux S. Radiolabeled α-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: From tritium to indium. J Mol Recognit 2003; 16:248-54. (Pubitemid 37240463)
13. Bard DR, Knight CG, Page-Thomas DP. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer 1990; 62:919-22.
14. Eberle AN. Proopiomelanocortin and the melanocortin peptides. In: Cone RD, ed. The Melanocortin Receptors. Totowa: Humana Press, 2000:3-67.
15. Eberle AN, Froidevaux S, Siegrist W. Melanocortins and melanoma. In: Cone RD, ed. The Melanocortin Receptors. Totowa: Humana Press, 2000:491-520.
16. Eves PC, MacNeil S, Haycock JW. α-Melanocyte-stimulating hormone, inflammation and human melanoma. Peptides 2006; 27:444-52. (Pubitemid 43162917)
17. De Luca M, Siegrist W, Bondanza S et al. α-Melanocyte stimulating hormone (α-MSH) stimulates normal human melanocyte growth by binding to high-affinity receptors. J Cell Sci 1993; 105:1079-84. (Pubitemid 23258669)
18. Siegrist W, Solca F, Stutz S et al. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989; 49:6352-58. (Pubitemid 20000936)
19. Ghanem GE, Comunale G, Libert A et al. Evidence for α-melanocyte- stimulating hormone (α-MSH) receptors on human malignant melanoma cells. Int J Cancer 1988; 41:248-55. (Pubitemid 18061152)
20. Siegrist W, Stutz S, Eberle AN. Homologous and heterologous regulation of α-melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines. Cancer Res 1994; 54:2604-10. (Pubitemid 24173745)
21. Jiang J, Sharma SD, Fink JL et al. Melanotropic peptide receptors: Membrane markers of human melanoma cells. Exp Dermatol 1996; 5:325-33. (Pubitemid 27060540)
22. Salazar-Onfray F, Lopez M, Lundqvist A et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer 2002; 87:414-22. (Pubitemid 34983565)
23. 111In]-DTPA-labeled analogues of α-MSH for the detection of MSH receptors in vitro and in vivo. Ann NY Acad Sci 1993; 680:445-7. (Pubitemid 23201034)
24. 111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo. Int J Cancer 1994; 58:749-55.
25. Eberle AN, Mild G. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods. J Recept Signal Transduct 2009; 29:1-37.
26. Wei L, Butcher C, Miao Y et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized α-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 2007; 48:64-72. (Pubitemid 47555377)
27. Giblin MF, Wang N, Hoffman TJ et al. Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 1998; 95:12814-8. (Pubitemid 28509480)
28. 3-labeled pyrazolyl-α-melanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol 2008; 35:91-9.
29. Bapst JP, Froidevaux S, Calame M et al. Dimeric DOTA-α-melanocyte- stimulating hormone analogs: Synthesis and in vivo characteristics of radiopeptides with high in vitro activity. J Recept Signal Transduct 2007; 27:383-409.
30. Heppeler A, Froidevaux S, Eberle AN et al. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7:971-94.
31. Froidevaux S, Calame-Christe M, Tanner H et al. Melanoma targeting with DOTA-α-melanocyte-stimulating hormone analogs: Structural parameters affecting tumor uptake and kidney uptake. J Nucl Med 2005; 46:887-95.
32. Bagutti C, Oestreicher M, Siegrist W et al. α-MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. J Recept Signal Transduct Res 1995; 15:427-42.
33. Froidevaux S, Calame-Christe M, Schuhmacher J et al. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004; 45:116-23. (Pubitemid 47611617)
34. Froidevaux S, Calame-Christe M, Tanner H et al. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 2002; 43:1699-706. (Pubitemid 35424997)
35. 111In-DOTA- rhenium cyclized α-MSH analog: A novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med 2001; 42:1847-55. (Pubitemid 34016356)
36. 111In-labeled DOTA conjugated rhenium-cyclized α-MSH analogues. J Med Chem 2002; 45:3048-56. (Pubitemid 34721526)
37. Miao Y, Owen NK, Whitener D et al. In vivo evaluation of 188Re-labeled α-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 2002; 101:480-487.
38. Cheng Z, Chen J, Quinn TP et al. Radioiodination of rhenium cyclized α-melanocyte stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res 2004; 64:1411-18. (Pubitemid 38235610)
39. Miao Y, Hoffman TJ, Quinn TP. Tumor targeting properties of 90Y and 177Lu labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 2005; 32:485-93. (Pubitemid 40854099)
40. Miao Y, Fisher DR, Quinn TP. Reducing renal uptake of 90Y and 177Lu labeled α-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 2006; 33:723-33. (Pubitemid 44247740)
41. Cheng Z, Zhang L, Graves E et al. Small animal PET of melanocortin 1 receptor expression using a 18F-labeled α-melanocyte stimulating hormone analog. J Nucl Med 2007; 48:987-94. (Pubitemid 46909928)
42. 111In-, 86Y- and 68Ga-labeled CHX-A-Re(Arg11) CCMSH. Nucl Med Biol 2009; 36:345-54.
43. Miao Y, Quinn TP. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 2008; 67:213-228.
44. 111In-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem 2008; 19:539-47. (Pubitemid 351294927)
45. Bernard BF, Krenning EP, Breeman WA et al. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 24:761-9.
46. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 1998; 25:201-12. (Pubitemid 28130048)
47. Bapst JP, Calame M, Tanner H et al. Glycosylated DOTA-α-melanocyte- stimulating hormone analogues for melanoma targeting: Influence of the site of glycosylation on in vivo biodistribution. Bioconjug Chem 2009; 20:984-93.
48. Cheng Z, Xiong Z, Subbarayan M et al. 64Cu-labeled α-melanocyte stimulating hormone analog for microPET imaging of melanocortin-1 receptor expression. Bioconjug Chem 2007; 18:765-72. (Pubitemid 47010796)
49. 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide. Nucl Med Biol 2009; 36:267-76.
50. 111In-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide. Bioconjug Chem 2009; 20:2162-8.